Reducing antibacterial development risk for GSK1322322 by exploring potential human dose regimens in nonclinical efficacy studies using immunocompetent rats.

about

Reducing antibacterial development risk for GSK1322322 by exploring potential human dose regimens in nonclinical efficacy studies using immunocompetent rats.

Item

http://www.wikidata.org/entity/Q40093553

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Reducing antibacterial develop ...... es using immunocompetent rats.

@en

type

Item

label

Reducing antibacterial develop ...... es using immunocompetent rats.

@en

prefLabel

Reducing antibacterial develop ...... es using immunocompetent rats.

@en

P1476

Reducing antibacterial develop ...... es using immunocompetent rats.

@en

P2093

Christine M Singley

http://www.w3.org/2001/XMLSchema#string

Magdalena Zalacain

http://www.w3.org/2001/XMLSchema#string

Peter DeMarsh

http://www.w3.org/2001/XMLSchema#string

Philippa Elefante

http://www.w3.org/2001/XMLSchema#string

Stephen Rittenhouse

http://www.w3.org/2001/XMLSchema#string

P2860

The estimation of the bactericidal power of the blood

Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae

Application of fluoroquinolone pharmacodynamics.

Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.

Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections.

Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.

Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage

Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.

Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.

Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs.

P31

scholarly article

P356

10.1128/AAC.00959-17

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer Hoover

P577

2017-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28807913

http://www.w3.org/2001/XMLSchema#string

P932

5655044

http://www.w3.org/2001/XMLSchema#string